Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2026, Vol. 40 ›› Issue (2): 29-34.doi: 10.6040/j.issn.1673-3770.0.2025.041
• Original Article • Previous Articles Next Articles
ZHANG Xiaohan, ZHU Liya, XIAO Yu, FU Xiaolong
CLC Number:
| [1] Asaad W, Volos P, Maksimov D, et al. AAV genome modification for efficient AAV production[J]. Heliyon, 2023, 9(4): e15071. doi:10.1016/j.heliyon.2023.e15071 [2] Martinez-Navio JM, Paulk NK, Gao GP. Editorial: “AAV gene therapy: immunology and immunotherapeutics”[J]. Front Immunol, 2021, 12: 822389. doi:10.3389/fimmu.2021.822389 [3] Liu D, Zhu MY, Zhang YQ, et al. Crossing the blood-brain barrier with AAV vectors[J]. Metab Brain Dis, 2021, 36(1): 45-52. doi:10.1007/s11011-020-00630-2 [4] Dhungel BP, Bailey CG, Rasko JEJ. Journey to the center of the cell: tracing the path of AAV transduction[J]. Trends Mol Med, 2021, 27(2): 172-184. doi:10.1016/j.molmed.2020.09.010 [5] Dasari S, Njiki S, Mbemi A, et al. Pharmacological effects of cisplatin combination with natural products in cancer chemotherapy[J]. Int J Mol Sci, 2022, 23(3): 1532. doi:10.3390/ijms23031532 [6] Ni MW, Zhou J, Zhu ZH, et al. Shikonin and cisplatin synergistically overcome cisplatin resistance of ovarian cancer by inducing ferroptosis via upregulation of HMOX1 to promote Fe(2+)accumulation[J]. Phytomedicine, 2023, 112: 154701. doi:10.1016/j.phymed.2023.154701 [7] Li Q, Chen SW, Wang X, et al. Cisplatin-based combination therapy for enhanced cancer treatment[J]. Curr Drug Targets, 2024, 25(7): 473-491. doi:10.2174/0113894501294182240401060343 [8] Elmorsy EA, Saber S, Hamad RS, et al. Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies[J]. Eur J Pharm Sci, 2024, 203: 106939. doi:10.1016/j.ejps.2024.106939 [9] Qiao XY, Li W, Zheng ZW, et al. Inhibition of the HMGB1/RAGE axis protects against cisplatin-induced ototoxicity via suppression of inflammation and oxidative stress[J]. Int J Biol Sci, 2024, 20(2): 784-800. doi:10.7150/ijbs.82003 [10] Lu XC, Yin N, Chen C, et al. Mangiferin alleviates cisplatin-induced ototoxicity in sensorineural hearing loss[J]. Biomed Pharmacother, 2024, 178: 117174. doi:10.1016/j.biopha.2024.117174 [11] Li Y, Zeng S, Zhou FJ, et al. Overexpression of XIAP inhibits cisplatin-induced hair cell loss[J]. Biochim Biophys Acta Mol Cell Res, 2022, 1869(4): 119204. doi:10.1016/j.bbamcr.2021.119204 [12] Li ZZ, Yao QX, Tian YX, et al. Trehalose protects against cisplatin-induced cochlear hair cell damage by activating TFEB-mediated autophagy[J]. Biochem Pharmacol, 2022, 197: 114904. doi:10.1016/j.bcp.2021.114904 [13] Liu ZY, Zhang HB, Hong GD, et al. Inhibition of Gpx4-mediated ferroptosis alleviates cisplatin-induced hearing loss in C57BL/6 mice[J]. Mol Ther, 2024, 32(5): 1387-1406. doi:10.1016/j.ymthe.2024.02.029 [14] Sung CYW, Hayase N, Yuen PST, et al. Macrophage depletion protects against cisplatin-induced ototoxicity and nephrotoxicity[J]. Sci Adv, 2024, 10(30): eadk9878. doi:10.1126/sciadv.adk9878 [15] Li M, Liu JW, Liu D, et al. Naringin attenuates cisplatin- and aminoglycoside-induced hair cell injury in the zebrafish lateral line via multiple pathways[J]. J Cell Mol Med, 2021, 25(2): 975-989. doi:10.1111/jcmm.16158 [16] Lyu AR, Kim SJ, Park MJ, et al. CORM-2 reduces cisplatin accumulation in the mouse inner ear and protects against cisplatin-induced ototoxicity[J]. J Adv Res, 2024, 64: 183-194. doi:10.1016/j.jare.2023.11.020 [17] Wang XL, Zhou YY, Wang DL, et al. Cisplatin-induced ototoxicity: From signaling network to therapeutic targets[J]. Biomed Pharmacother, 2023, 157: 114045. doi:10.1016/j.biopha.2022.114045 [18] Shen XJ, Wang HB, Weng CH, et al. Caspase 3/GSDME-dependent pyroptosis contributes to chemotherapy drug-induced nephrotoxicity[J]. Cell Death Dis, 2021, 12(2): 186. doi:10.1038/s41419-021-03458-5 [19] Xu JJ, Zhang B, Chu ZL, et al. Wogonin alleviates cisplatin-induced cardiotoxicity in mice via inhibiting gasdermin D-mediated pyroptosis[J]. J Cardiovasc Pharmacol, 2021, 78(4): 597-603. doi:10.1097/FJC.0000000000001085 [20] Liu X, Xia SY, Zhang ZB, et al. Channelling inflammation: gasdermins in physiology and disease[J]. Nat Rev Drug Discov, 2021, 20(5): 384-405. doi:10.1038/s41573-021-00154-z [21] Bertheloot D, Latz E, Franklin BS. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death[J]. Cell Mol Immunol, 2021, 18(5): 1106-1121. doi:10.1038/s41423-020-00630-3 [22] Zhang ZB, Zhang Y, Lieberman J. Lighting a fire: can we harness pyroptosis to ignite antitumor immunity?[J]. Cancer Immunol Res, 2021, 9(1): 2-7. doi:10.1158/2326-6066.CIR-20-0525 [23] Ai YL, Wang WJ, Liu FJ, et al. Mannose antagonizes GSDME-mediated pyroptosis through AMPK activated by metabolite GlcNAc-6P[J]. Cell Res, 2023, 33(12): 904-922. doi:10.1038/s41422-023-00848-6 [24] Loveless R, Bloomquist R, Teng Y. Pyroptosis at the forefront of anticancer immunity[J]. J Exp Clin Cancer Res, 2021, 40(1): 264. doi:10.1186/s13046-021-02065-8 [25] Zhang N, Zhang J, Yang YX, et al. A palmitoylation-depalmitoylation relay spatiotemporally controls GSDMD activation in pyroptosis[J]. Nat Cell Biol, 2024, 26(5): 757-769. doi:10.1038/s41556-024-01397-9 [26] Xing YQ, Zhang FY, Ji PP, et al. Efficient delivery of GSDMD-N mRNA by engineered extracellular vesicles induces pyroptosis for enhanced immunotherapy[J]. Small, 2023, 19(20): e2204031. doi:10.1002/smLl.202204031 [27] Li LR, Chen L, Sun ZJ. Igniting hope: harnessing NLRP3 inflammasome-GSDMD-mediated pyroptosis for cancer immunotherapy[J]. Life Sci, 2024, 354: 122951. doi:10.1016/j.lfs.2024.122951 [28] Balasubramanian A, Hsu AY, Ghimire L, et al. The palmitoylation of gasdermin D directs its membrane translocation and pore formation during pyroptosis[J]. Sci Immunol, 2024, 9(94): eadn1452. doi:10.1126/sciimmunol.adn1452 [29] Crane R, Conley SM, Al-Ubaidi MR, et al. Gene therapy to the retina and the cochlea[J]. Front Neurosci, 2021, 15: 652215. doi:10.3389/fnins.2021.652215 [30] Taiber S, Cohen R, Yizhar-Barnea O, et al. Neonatal AAV gene therapy rescues hearing in a mouse model of SYNE4 deafness[J]. EMBO Mol Med, 2021, 13(2): e13259. doi:10.15252/emmm.202013259 [31] Marcovich I, Baer NK, Shubina-Oleinik O, et al. Optimized AAV vectors for TMC1 gene therapy in a humanized mouse model of DFNB7/11[J]. Biomolecules, 2022, 12(7): 914. doi:10.3390/biom12070914 [32] Qi JY, Zhang LY, Tan FZ, et al. Preclinical efficacy and safety evaluation of AAV-OTOF in DFNB9 mouse model and nonhuman primate[J]. Adv Sci, 2024, 11(3): 2306201. doi:10.1002/advs.202306201 [33] Qi JY, Tan FZ, Zhang LY, et al. AAV-mediated gene therapy restores hearing in patients with DFNB9 deafness[J]. Adv Sci, 2024, 11(11): 2306788. doi:10.1002/advs.202306788 [34] Zhang L, Song WA, Li H, et al. 4-octyl itaconate alleviates cisplatin-induced ferroptosis possibly via activating the NRF2/HO-1 signalling pathway[J]. J Cell Mol Med, 2024, 28(7): e18207. doi:10.1111/jcmm.18207 [35] Jiang YM, Li ZZ, Ma Q, et al. Aucubin protects mouse cochlear hair cells from cisplatin-induced ototoxicity via activation of the PI3K/AKT/STAT3 pathway[J]. Biochem Pharmacol, 2023, 209: 115440. doi:10.1016/j.bcp.2023.115440 [36] Bovee S, Klump GM, Köppl C, et al. The stria vascularis: renewed attention on a key player in age-related hearing loss[J]. Int J Mol Sci, 2024, 25(10): 5391. doi:10.3390/ijms25105391 [37] Lang HN, Noble KV, Barth JL, et al. The stria vascularis in mice and humans is an early site of age-related cochlear degeneration, macrophage dysfunction, and inflammation[J]. J Neurosci, 2023, 43(27): 5057-5075. doi:10.1523/JNEUROSCI.2234-22.2023 [38] Fang J, Li ZZ, Wang PJ, et al. Inhibition of the NLRP3 inflammasome attenuates spiral ganglion neuron degeneration in aminoglycoside-induced hearing loss[J]. Neural Regen Res, 2025, 20(10): 3025-3039. doi:10.4103/NRR.NRR-D-23-01879 |
| [1] | ZHANG Jingyi, DONG Xiangyi, MU Yakui, SONG Xicheng. Research progress on pyroptosis in otorhinolaryngology diseases [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(4): 140-148. |
| [2] | YANG Yingling, GOU Haocheng, FENG Jun. Review of pyroptosis molecular mechanism and applications in head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(4): 160-165. |
| [3] | YUAN Yue, FU Shengyao, JIANG Yan, CHEN Min. Research progress of pyroptosis in chronic airway inflammatory disease [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(4): 166-171. |
| [4] | ZHOU Jiamin, SONG Yuwan, SUN Yan. Research progress of pyroptosis in senile degenerative diseases [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(4): 172-180. |
| [5] | LIU Zhen,SONG Xicheng. Mechanisms and research progress of pyroptosis in allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 123-129. |
|